Mylan’s India-based subsidiary, Mylan Pharmaceuticals Private Ltd., has been named an exclusive business partner for Gilead Sciences’ branded medicines in India. Mylan will market and distribute Gilead's HIV therapies Viread, including its indication for chronic hepatitis B virus (HBV) infection, Truvada, and Stribild, as well as AmBisome, a treatment for life-threatening, systemic fungal infections, and visceral leishmaniasis, a parasitic disease. Mylan will also manage regulatory and pharmacovigilance activity, such as adverse event reporting, and medical education initiatives.
In 2006 Gilead granted Mylan rights to manufacture and sell generic versions of its HIV therapies in India and as many as 111 developing countries where HIV is endemic. Mylan will continue to maintain these rights, in addition to those in the new agreement.
Mylan chief executive officer Heather Bresch, said, "This further extension of our collaboration with Gilead builds off of our existing successful partnership manufacturing and supplying high-quality, cost-effective generic antiretroviral therapy for those in resource challenged countries, delivering on our mission of providing access to high quality medicine to the world's seven billion people."
Gilead's executive vice president of Corporate and Medical Affairs, Gregg H. Alton, said, "The appointment of Mylan as our branded medicine business partner in India is a result of their strong knowledge of the Indian healthcare system and demonstrated capabilities of supporting and distributing antiretroviral therapies. We have established an excellent working relationship with Mylan over the past few years, and believe that their operations in India will allow the company to best serve the needs of patients in that country."